118
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Characterizing the Ligand-Binding Landscape of Zika NS3 Helicase-Promising Lead Compounds As Potential Inhibitors

, &
Pages 261-273 | Received 25 Jan 2017, Accepted 10 Apr 2017, Published online: 19 Jun 2017
 

Abstract

Aim: This study aims to provide insight into the binding features of the ATPase and ssRNA sites of the NS3 helicase. Methods: Clinically approved Flavivirus inhibitors were docked to the corresponding active sites of the protein, and the three best compounds were validated with molecular dynamic simulations. Result: Binding of Ivermectin to ssRNA site and Lapachol and HMC-HO1α to the ATPase site allowed for conformational rigidity of the Zika NS3 helicase, thus stabilizing residue fluctuations and allowing for protein stability. Favorable free binding energies were also noted between compounds and the helicase, thus supporting the intermolecular forces at the helicase active site. Conclusion: The pharmacophoric characteristics found in Lapachol, HMC-HO1α and Ivermectin may be utilized in the design of a potent hybrid drug that is able to show efficient inhibition of a multitude of diseases including the detrimental co-infection of Zika virus, dengue and chikungunya.

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at:www.tandfonline.com/doi/full/10.2217/fvl-2017-0014

Financial & competing interests disclosure

The authors acknowledge the College of Health Sciences, UKZN, and the National Research Foundation for their financial support and the Center for High Performance Computing [Citation53] for their computational resources.

The authors have no other relevantaffiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.